Peroxisome proliferator-activated receptors: Targets for the treatment of metabolic illnesses (Review)

Molecular Medicine Reports

Volumn 1, Issue 3, 2008, Pages 317-324

  Moore Carrasco, Rodrigo ^a   Bustamante, Mauricio Poblete ^a   Guerra, Oscar González ^b   Madariaga, Elba Leiva ^a   Escudero, Veronica Mujica ^a   Arellano, Claudio Aranguez ^a   Iván, Palomo ^a  

^a UNIVERSIDAD DE TALCA   (Chile)

^b Hospital San Agustín   (Chile)

Author keywords

Cardiovascular diseases; Diabetes mellitus; Fibrates; Peroxisome proliferator activated receptor; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 5 (2,4 DIOXO 5 THIAZOLIDINYLMETHYL) 2 METHOXY N [4 (TRIFLUOROMETHYL)BENZYL]BENZAMIDE; BEZAFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GLIBENCLAMIDE; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; MURAGLITAZAR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PIOGLITAZONE; PLACEBO; RAGAGLITAZAR; RAMIPRIL; ROSIGLITAZONE; TELMISARTAN; TESAGLITAZAR; TROGLITAZONE;

CATALYST; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES CONTROL; DIABETIC RETINOPATHY; DRUG INHIBITION; DRUG MEGADOSE; DRUG TARGETING; ENZYME ACTIVITY; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; INSULIN SENSITIVITY; LIVER TOXICITY; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; SIDE EFFECT; STENOSIS; STROKE; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 69249083643     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.1.3.317     Document Type: Review

References (86)

1. Lalwani ND, Reddy MK, Qureshi SA, et al: Evaluation of selected hypolipidemic agents for the induction of peroxisomal enzymes and peroxisome proliferation in the rat liver. Hum Toxicol 2: 27-48, 1983.
2. Desvergne B and Wahli W: Peroxisome proliferator-activated recptor: Nuclear control of metabolism. Endocr Rev 20: 649-688, 1999. (Pubitemid 30650602)
3. Juge-Aubry CE, Hammar E, Siegrist-Kaiser C, et al: Regulation of the transcriptional activity of the peroxisome proliferator-activated receptor alpha by phosphorylation of a ligand-independent transactivating domain. J Biol Chem 274: 10505-10510, 1999. (Pubitemid 129518347)
4. Wahli W, Braissant O and Desvergne B: Peroxisome proliferator activated receptors: transcriptional regulators of adipogenesis, lipid metabolism and more. Chem Biol 2: 261-266, 1995.
5. Braissant O, Foufelle F, Scotto C, Dauca M and Wahli W: Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPARα, β and γ in the adult rat. Endocrinology 137: 354-366, 1996.
6. Schoonjans K, Staels B and Auwerx J: Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 37: 907-925, 1996. (Pubitemid 26182326)
7. Lee S, Pineau T, Drago J, Lee E, Owens J, Kroetz D, Fernandez-Salguero P-M, Westphal H and Gonzalez F: Targeted disruption of the α isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol 15: 3012-3022, 1995.
8. Knauf C, Rieusset J, Foretz M, et al: Peroxisome proliferator-activated receptor-alpha-null mice have increased white adipose tissue glucose utilization, GLUT4, and fat mass: Role in liver and brain. Endocrinology 147: 4067-4078, 2006.
9. Cuzzocrea S, Mazzon E, Di Paola R, et al: The role of the peroxisome proliferator-activated receptor-alpha (PPAR-alpha) in the regulation of acute inflammation. J Leukoc Biol 79: 999-1010, 2006. (Pubitemid 44835587)
10. Delayre-Orthez C, Becker J, Guenon I, et al: PPAR alpha downregulates airway inflammation induced by lipopolysaccharide in the mouse. Respir Res 6: 91-101, 2005. (Pubitemid 41410146)
11. Li S, Gokden N, Okusa MD, et al: Anti-inflammatory effect of fibrate protects from cisplatin-induced ARF. Am J Physiol Renal Physiol 289: 469-480, 2005. (Pubitemid 41003677)
12. Loichot C, Jesel L, Tesse A, et al: Deletion of peroxisome proliferator-activated receptor-alpha induces an alteration of cardiac functions. Am J Physiol Heart Circ Physiol 291: 161-166, 2006.
13. Guerre-Millo M, Rouault C, Poulain P, et al: PPAR-alpha-null mice are protected from high-fat diet-induced insulin resistance. Diabetes 50: 2809-2814, 2001. (Pubitemid 33733132)
14. Marx N, Kehrle B, Kohlhammer K, et al: PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res 90: 703-710, 2002. (Pubitemid 34640890)
15. Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ and Wahli W: The PPARα leukotriene B4 pathway to inflammatory control. Nature 384: 39-43, 1996.
16. Marx N, Sukhova GK, Collins T, Libby P and Plutzky J: PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 99: 3125-3131, 1999. (Pubitemid 29289077)
17. Kleeman R, Gervois PP, Verschuren L, et al: Fibrates downregulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFκB-C/EBP-β complex formation. Blood 101: 545-551, 2003. (Pubitemid 36077576)
18. Sun Z and Andersson R: NFκB activation and inhibition: a review. Shock 18: 99-106, 2002.
19. Neve BP, Corseaux D, Chinetti G, et al: PPARα agonists inhibit tissue factor expression in human THP-1 cells, monocytes and macrophages. Circulation 103: 207-212, 2001. (Pubitemid 32095404)
20. Faveeuw C, Fougeray S, Angeli V, et al: Peroxisome proliferator-activated receptor γ activators inhibit interleukin-12 production in murine dendritic cells. FEBS Lett 486: 261-266, 2000.
21. Clark RB, Bishop Bailey D, Estrada Hernandez T, Hla T, Puddington L and Padula SJ: The nuclear receptor PPARγ and immunoregulation: PPARγ mediates inhibition of helper T cell responses. J Immunol 164: 1364-1371, 2000. (Pubitemid 30067250)
22. Staels B, Vu-Dac N, Kosykh VA, et al: Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J Clin Invest 95: 705-712, 1995.
23. Torra IP, Chinetti G, Duval C, Fruchart JC and Staels B: Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice. Curr Opin Lipidol 12: 245-254, 2001. (Pubitemid 32521948)
24. De Silva HV, Lauer SJ, Wang J, et al: Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E. J Biol Chem 269: 2324-2335, 1994. (Pubitemid 24035450)
25. Chapman MJ: Fibrates in 2003: therapeutic action in atherogenic dyslipidemia and future perspectives. Atherosclerosis 171: 1-13, 2003.
26. Yoshida H, Ishikawa T, Ayaori M, et al: Beneficial effect of gemfibrozil on the chemical composition and oxidative susceptibility of low density lipoprotein: a randomized, double-blind, placebo-controlled study. Atherosclerosis 139: 179-187, 1998. (Pubitemid 28341881)
27. Chinetti G, Lestavel S, Bocher V, et al: PPAR-α and PPAR-δ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 7: 53-58, 2001. (Pubitemid 32095642)
28. Argmann C, Edwards J, Sawyez C, et al: Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl-CoA reductase inhibition. J Biol Chem 280: 22212-22221, 2005.
29. Staels B and Fruchart JC: Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 54: 2460-2470, 2005. (Pubitemid 41134276)
30. Martin G, Duez H, Blanquart C, et al: Statin-induced inhibition of the Rho-signaling pathway activates PPARa and induces HDL apoA-I. J Clin Invest 107: 1423-1432, 2001. (Pubitemid 32522036)
31. Tenenbaum A, Fisman E and Motro M: Metabolic syndrome and type 2 diabetes mellitus: focus on peroxisome proliferator activated receptors. Cardiovasc Diabetol 2: 4-11, 2003. (Pubitemid 38751109)
32. The BIP Study Group: Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease The Bezafibrate Infarction Prevention (BIP) Study. Circulation 102: 21-27, 2000.
33. Willa AH and Bruemmer D: Peroxisome proliferator-activated receptor: Implications for cardiovascular disease. Hipertensión 43: 297-305, 2004. (Pubitemid 38174129)
34. Manresa JM, Zamora A, Tomas M, et al: Relationship of classical and non-classical risk factors with genetic variants relevant to coronary heart disease. Eur J Cardiovasc Prev Rehabil 13: 738-744, 2006. (Pubitemid 44454846)
35. Tai ES, Collins D, Robins SJ, et al: The L162V polymorphism at the peroxisome proliferator activated receptor alpha locus modulates the risk of cardio-vascular events associated with insulin resistance and diabetes mellitus: the Veterans Affairs HDL Intervention Trial (VA-HIT). Atherosclerosis 187: 153-160, 2006. (Pubitemid 43833359)
36. Tai ES, Corella D, Demissie S, et al: Framingham Heart Study. Polyunsaturated fatty acids interact with the PPARA-L162V polymorphism to affect plasma triglyceride and apolipoprotein C-III concentrations in the Framingham Heart Study. J Nutr 135: 397-403, 2005. (Pubitemid 40365194)
37. Robitaille J, Brouillette C, Houde A, et al: Association between the PPARalpha-L162V polymorphism and components of the metabolic syndrome. J Hum Genet 49: 482-489, 2004. (Pubitemid 39314367)
38. Hansen L, Ekstrom CT, Tabanera Y, et al: The Pro12Ala variant of the PPARG gene is a risk factor for peroxisome proliferator-activated receptor-gamma/alpha agonist-induced edema in type 2 diabetic patients. J Clin Endocrinol Metab 91: 3446-3450, 2006. (Pubitemid 44402117)
39. Ansquer JC, Foucher C, Rattier S, Taskinen MR and Steiner G: DAIS Investigators. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from The Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 45: 485-493, 2005. (Pubitemid 40341327)
40. Vakkilainen J, Steiner G, Ansquer JC, et al: DAIS group. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 107: 1733-1737, 2003.
41. McLaughlin PR and Gladstone P: Diabetes Atherosclerosis Intervention Study (DAIS): quantitative coronary angiographic analysis of coronary artery atherosclerosis. Cathet Cardiovasc Diagn 44: 249-256, 1998.
42. Elkeles RS, Diamond JR, Poulter C, et al: Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: The St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care 21: 641-648, 1998.
43. Elkeles RS, Diamond JR, El-Bahghouti N, et al: Relative fasting hypoinsulinaemia and ultrasonically measured early arterial disease in type 2 diabetes. The SENDCAP Study Group, St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention Study. Diabet Med 13: 247-253, 1996.
44. Robinson JG: Update on PPAR agonists: The clinical significance of FIELD and PROACTIVE. Curr Atheroscler Rep 9: 64-71, 2007.
45. The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (The FIELD Study): randomised controlled trial. Lancet 366: 1849-1861, 2005.
46. Barbier O, Pineda Torra I, Duguay Y, et al: Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 22: 717-726, 2002. (Pubitemid 34517781)
47. Yki-Järvinen H: Thiazolidinediones. N Engl J Med 351: 1106-1118, 2004.
48. Inzucchi S: Oral antihyperglycemic therapy for type 2 diabetes. JAMA 287: 360-372, 2002.
49. Vamecq J and Latruffe N: Medical significance of peroxisome proliferator-activated receptors. Lancet 354: 141-148, 1999. (Pubitemid 29313157)
50. Goldberg R, Kendall D, Deeg M, et al: A comparison of lipid and glycemic effect of pioglitazone and rosiglitazone in patients with type 2 diabetes mellitus and dyslipidemia. Diabetes Care 28: 1547-1554, 2005. (Pubitemid 40923063)
51. Kharroubi I, Lee CH, Hekerman P, et al: BCL-6: a possible missing link for anti-inflammatory PPAR-delta signalling in pancreatic beta cells. Diabetologia 49: 2350-2358, 2006. (Pubitemid 44359096)
52. Lalloyer F, Vandewalle B, Percevault F, et al: Peroxisome proliferator-activated receptor alpha improves pancreatic adaptation to insulin resistance in obese mice and reduces lipotoxicity in human islets. Diabetes 55: 1605-1613, 2006. (Pubitemid 44324112)
53. Kawai T, Hirose H, Seto Y, et al: Troglitazone ameliorates lipotoxicity in the beta cell line INS-1 expressing PPAR gamma. Diabetes Res Clin Pract 56: 83-92, 2002. (Pubitemid 34226623)
54. Harrity T, Farrelly D, Tieman A, et al: Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice. Diabetes 55: 240-248, 2006. (Pubitemid 43343321)
55. Welters HJ, McBain SC, Tadayyon M, Scarpello JH, Smith SA and Morgan NG: Expression and functional activity of PPARgamma in pancreatic beta cells. Br J Pharmacol 142: 1162-1170, 2004. (Pubitemid 39093013)
56. Dormandy J, Charbonnel B, Eckland DJ, et al on behalf of the PROactive investigators: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (Prospective Pioglitazone Clinical Trial in Macrovascular Events): a Randomised Controlled Trial. Lancet 366: 1279-1289, 2005. (Pubitemid 41416583)
57. Snitker S, Watanabe RM, Ani I, et al: Troglitazone in Prevention of Diabetes (TRIPOD) Study. Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-gamma2 gene variant: results from the Troglitazone in Prevention of Diabetes (TRIPOD) Study. Diabetes Care 27: 1365-1368, 2004.
58. Ratner RE: The Diabetes Prevention Program Research. An update on the Diabetes Prevention Program. Endocr Pract 12: 20-24, 2006.
59. Knowler WC, Hamman RF, Edelstein SL, et al: Diabetes Prevention Program Research Group. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 54: 1150-1156, 2005.
60. Pfutzner A, Schneider CA and Forst T: Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects. Expert Rev Cardiovasc Ther 4: 445-459, 2006. (Pubitemid 44304550)
61. Hanefeld M, Marx N, Pfutzner A, et al: Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: The PIOSTAT Study. J Am Coll Cardiol 49: 290-297, 2007. (Pubitemid 46110954)
62. DREAM Trial Investigators, Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G, Diaz R, Avezum A, Lanas F, Probstfield J, Fodor G and Holman RR: Effect of ramipril on the incidence of diabetes. N Engl J Med 355: 1551-1562, 2006.
63. Stevens RJ, Coleman RL, Adler AI, Stratton IM, Matthews DR and Holman RR: Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66. Diabetes Care 27: 201-217, 2004.
64. Pfutzner A and Forst T: High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus. Diabetes Technol Ther 8: 28-36, 2006.
65. Nissen S, Wolsky K and Topol E: Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 294: 2581-2586, 2005. (Pubitemid 41697247)
66. Kendall DM, Rubin CJ, Mohideen P, et al: Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a double-blind, randomized, pioglitazone-comparative study. Diabetes Care 29: 1016-1023, 2006. (Pubitemid 44115238)
67. Goldstein BJ, Rosenstock J, Anzalone D, Tou C and Ohman KP: Effect of tesaglitazar, a dual PPARalpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial. Curr Med Res Opin 22: 2575-2590, 2006. (Pubitemid 46048373)
68. Marx N, Froehlich J, Siam L, et al: Anti-diabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 23: 283-288, 2003. (Pubitemid 36231941)
69. Sidhu JS, Cowan D and Kaski JC: The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol 42: 1757-1763, 2003. (Pubitemid 37433654)
70. Evans R, Grant B and Wang XY: PPARs and the complex jouney to obesity. Nat Med 10: 1-7, 2004.
71. Yoon JC, Puigserver P, Chen G, et al: Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature 413: 131-138, 2001. (Pubitemid 32867868)
72. Iglarz M, Touyz RM, Amiri F, Lavoie MF, Diep QN and Schiffrin EL: Effect of peroxisome proliferator-activated receptor-α and -γ activators on vascular remodeling in endothelin-dependent hypertension. Arterioscler Thromb Vasc Biol 23: 45-51, 2003. (Pubitemid 36091624)
73. Wang YX, Lee CH, Tiep S, Yu RT, Ham J, Kang H and Evans RM: Peroxisome proliferators-activated receptor δ activates fat metabolism to prevent obesity. Cell 113: 159-170, 2003. (Pubitemid 36514968)
74. Mensink M, Hesselink MK, Russell AP, Schaart G, Sels JP and Schrauwen P: Improved skeletal muscle oxidative enzyme activity and restoration of PGC-1 alpha and PPARbeta/delta gene expression upon rosiglitazone treatment in obese patients with type 2 diabetes mellitus. Int J Obes 31: 1302-1310, 2007. (Pubitemid 47172612)
75. Shiroshita-Takeshita A, Brundel BJ, Burstein B, et al: Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure. Cardiovasc Res 74: 75-84, 2007. (Pubitemid 46366949)
76. Srivastava PM, Calafiore P, MacIsaac RJ, Hare DL, Jerums G and Burrell LM: Thiazolidinediones and congestive heart failure - exacerbation or new onset of left ventricular dysfunction? Diabet Med 21: 945-950, 2004.
77. Nichols GA and Gomez-Caminero A: Weight changes following the initiation of new anti-hyperglycaemic therapies. Diabetes Obes Metab 9: 96-102, 2007.
78. Chiang CK, Ho TI, Peng YS, et al: Rosiglitazone in diabetes control in hemodialysis patients with and without viral hepatitis infection: effectiveness and side effects. Diabetes Care 30: 3-7, 2007.
79. Fonseca V: Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am J Med 115: 42S-48S, 2003.
80. Schupp M, Clemenz M, Gineste R, et al: Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes 54: 3442-3452, 2005. (Pubitemid 43334334)
81. Benndorf RA, Rudolph T, Appel D, et al: Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension. Metabolism 55: 1159-1164, 2006. (Pubitemid 44219053)
82. Erbe DV, Gartrell K, Zhang YL, et al: Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists. Vascul Pharmacol 45: 154-162, 2006. (Pubitemid 44716729)
83. Janke J, Schupp M, Engeli S, et al: Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-gamma activation. J Hypertens 24: 1809-1816, 2006.
84. Yoshida T, Yamagishi S, Nakamura K, et al: Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation. Diabetologia 49: 3094-3099, 2006. (Pubitemid 44730314)
85. Negro R and Hassan H: The effects of telmisartan and amlodipine on metabolic parameters and blood pressure in type 2 diabetic, hypertensive patients. J Renin Angiotensin Aldosterone Syst 7: 243-246, 2006. (Pubitemid 46380776)
86. Nissen SE and Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457-2471, 2007. (Pubitemid 46919772)